GlassScriptPhysician profile
Bryson Thomas Whalen
NPI 1255727301
$4,226.42
in general payments reported to CMS, 2019-2025
28 companies · $236 in 2025
The $236 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $241 · 2020: $830 · 2021: $1,749 · 2022: $1,116 · 2023: $36.21 · 2024: $17.71 · 2025: $236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $290.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $970.86 | 2019-2022 | |
| Avion Pharmaceuticals | $655.66 | 2020-2022 | |
| Novo Nordisk INC | $428.40 | 2020-2022 | |
| Organon LLC | $338.28 | 2021-2025 | Jada System |
| Takeda Pharmaceuticals U.S.A., INC. | $286.53 | 2020-2022 | |
| Mayne Pharma Commercial LLC | $268.94 | 2021-2023 | |
| Myovant Sciences INC. | $240.14 | 2021-2022 | |
| Astellas Pharma US INC | $155.58 | 2021-2023 | Veozah |
| Exeltis, USA INC. | $123.96 | 2020-2022 | |
| Agile Therapeutics, INC. | $98.12 | 2021-2024 | Twirla |
| Merck Sharp & Dohme LLC | $84.15 | 2019-2021 | |
| Lupin INC. | $82.33 | 2019-2021 | |
| Amag Pharmaceuticals, INC. | $63.11 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $58.37 | 2021 | |
| Pfizer INC. | $54.78 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $45.06 | 2020 | |
| Mylan Pharmaceuticals INC. | $44.19 | 2021-2022 | |
| Ascend Therapeutics US, LLC | $42.29 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $32.10 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.62 | 2021-2023 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $27.37 | 2021-2022 | |
| Daiichi Sankyo INC. | $20.24 | 2020 | |
| Hologic Sales and Service, LLC | $18.42 | 2021 | |
| Alydia Health | $13.83 | 2021 | |
| Evofem Biosciences, INC. | $13.57 | 2021 | |
| Therapeuticsmd, INC. | $11.19 | 2021 | |
| Dysis Medical, INC. | $11.09 | 2021 | |
| Meditrina | $10.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryson Whalen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.